ClinicalTrials.gg
RecruitingNCT06107517DREAMS-OTUpdated Mar 30, 2026

Reducing Delirium After CABG Surgery With Early Activation and Sleep-Promoting Routines

An interventional study of DREAMS-OT in Delirium, Postoperative, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Emergence Delirium with a site in Singapore — 3 open to participants now, 3 under way, none of them phase 3. Emergence Delirium · Singapore.

Started
2024
the only one that year
No phase
4 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
5 of 10
National University Hospital, Singapore

Among the 10 studies in Emergence Delirium with a site in Singapore, this one is the only one that started in 2024, is one of 4 with no phase, and was the 8th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

3 of the 10 studies in Emergence Delirium with a site in Singapore are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Emergence Delirium with a site in Singapore, or all of them as a file.
02

Study summary

The goal of this randomized-controlled trial (RCT) is to compare the effectiveness of the DREAMS-OT intervention with standard care in reducing post-Coronary Artery Bypass Graft (CABG) surgery delirium in patients undergoing CABG surgery.

The aims of the study are:

  1. To determine if early and intensive OT will lower the incidence of post-op delirium in CABG patients compared to standard are.
  2. To determine the cost effectiveness of the DREAMS-OT intervention.

The study team will compare intervention group and standard care group (control group) to see if there is a reduction in the incidence of delirium in patients 5 days post-CABG.

03

Conditions studied

  • Delirium, Postoperative

Keywords

  • Delirium
  • Coronary Artery Bypass Grafting
  • Occupational Therapy
  • Intensive Care Units
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients deemed medically suitable for elective CABG surgery
  • Patients aged 21 years and above
  • Patients who are English or Mandarin speaking.
  • Patients who are able to provide consent

Exclusion criteria

Exclusion Criteria:

  • Patients who speak other languages are excluded due to the language requirements of certain outcome measures.
  • Patients with premorbid severe hearing impairment, severe cognitive impairment, progressive neurological disorders and psychological disorders will be excluded.
  • Patients with surgical complications resulting in profuse bleeding from any invasive sites, septic shock unresponsive to maximal treatment, and those who are moribund or have an expected mortality within 48 hours will be excluded.
  • Pregnant women will also be excluded from the study as well.
  • Patients who develop delirium before initiation of the treatment are also excluded from the study.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    DREAMS-OT Arm (Intervention Group)

    Patients will receive an early and intensive occupational therapy protocol starting within the first 15 hours after extubation.

    Other: DREAMS-OT

  • No intervention
    Standard Care Arm (Control Group)

    Standard care OT as per current ICU setting

Interventions

  • OtherDREAMS-OT

    Patients will receive the DREAMS-OT protocol 3 times per day, 20 minutes per therapy session. Intervention frequency will be confirmed with a feasibility trial. If not feasible to maintain 3 times per day, the intervention will still be maintained at the same intensity of 1 hour per day, with a graded approach.

06

What researchers measure

Primary outcomes

  1. Delirium

    Incidence of delirium from Day 1 to Day 5 post-CABG are measured using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) assessment tool.

    Time frame: Day 1 of post-CABG (AM and PM), Day 2 of post-CABG (AM and PM), Day 3 of post-CABG (AM and PM), Day 4 of post-CABG (AM and PM), Day 5 of post-CABG (AM and PM); (+/- 1 day for last measurement)

  2. Delirium

    Incidence of delirium from Day 1 to Day 5 post-CABG are measured using the 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM).

    Time frame: Day 1 of post-CABG (AM and PM), Day 2 of post-CABG (AM and PM), Day 3 of post-CABG (AM and PM), Day 4 of post-CABG (AM and PM), Day 5 of post-CABG (AM and PM); (+/- 1 day for last measurement)

Secondary outcomes

  1. Length of Stay

    Length of stay in ICU and hospital in days

    Time frame: 3-months post-CABG (+/- 1 month)

  2. Duration of Delirium

    Duration of delirium in subgroup of participants who develop delirium

    Time frame: Day 1 of post-CABG (AM and PM), Day 2 of post-CABG (AM and PM), Day 3 of post-CABG (AM and PM), Day 4 of post-CABG (AM and PM), Day 5 of post-CABG (AM and PM)

  3. Sleep Quality

    Sleep quality (Duration of Total Sleep, Light Sleep, Deep Sleep and Rapid Eye Movement (REM) Sleep in hours) as measured with Oura Ring, a wearable sleep tracking device

    Time frame: 2 weeks prior to operation (Baseline measurement, +/- 2 weeks), Day 1 of post-CABG, Day 2 of post-CABG (+/- 1 day), 3 months post-CABG for 3 consecutive days (+/- 1 month)

  4. Functional Status

    Functional status measured using Acute Care Index of Function (ACIF). The score ranges from 0 - 176 (or 206 for wheelchair-bound participants), with higher scores indicating better functional performance.

    Time frame: Day 5 of post-CABG (+/- 1 day)

  5. Physical Status

    Physical status measured using Functional Independence Measure (FIM). The score ranges from 0 - 126, with higher scores indicating better physical status.

    Time frame: Day 5 of post-CABG (+/- 1 day), 3 months post-CABG (+/- 1 month)

  6. Cognitive status

    Cognitive status measurement using Montreal Cognitive Assessment (MoCA). The score ranges from 0 - 30, with higher scores indicating better cognitive status.

    Time frame: 2 weeks prior to operation (Baseline measurement, +/- 2 weeks), Day 5 of post-CABG (+/- 1 day), 3 months post-CABG (+/- 1 month)

  7. Psychological State

    Psychological state measured using the Hospital Anxiety and Depression Scale (HADS). The score ranges from 0 - 21, with higher scores indicating worse psychological state.

    Time frame: 2 weeks prior to operation (Baseline measurement, +/- 2 weeks), Day 5 of post-CABG (+/-1 day), 3 months post-CABG (+/- 1 month)

  8. Cognitive status

    Cognitive status measured using the Weekly Calendar Planning Activity (WCPA) is assessed using an efficiency score derived from accuracy and time to completion. Higher scores indicate better performance. The score is a continuous variable without a fixed range.

    Time frame: 3-months post-CABG (+/- 1 month)

Other outcomes

  1. Richmond Agitation Sedation Scale (RASS)

    RASS which will be used for CAM-ICU assessment (primary outcome measure). The scores range from -5 to +4, with higher score indicating greater agitation and lower scores indicating deeper sedation.

    Time frame: Day 1 of post-CABG (AM and PM), Day 2 of post-CABG (AM and PM), Day 3 of post-CABG (AM and PM), Day 4 of post-CABG (AM and PM), Day 5 of post-CABG (AM and PM)

  2. European System for Cardiac Operative Risk Evaluation (EuroSCORE) 2

    EuroSCORE 2 is used to assess the risk of heart surgery of participants before their CABG surgery. The score ranges from 0% - 100%, with higher percentage indicating worse outcome or greater predicted mortality risk.

    Time frame: 2 weeks prior to operation (Baseline measurement, +/- 2 weeks)

  3. Charlson Comorbidity Index (CCI)

    Predicts mortality for participant before CABG surgery. The score ranges from 0 - 37, with higher score indicating worse outcome or greater comorbidity burden and mortality risk.

    Time frame: 2 weeks prior to operation (Baseline measurement, +/- 2 weeks)

  4. Clinical Frailty Index (CFI)

    Measure health status of participant before surgery. The score range from 0 - 9, with higher score indicating worse outcome.

    Time frame: 2 weeks prior to operation (Baseline measurement, +/- 2 weeks)

  5. ICU Mobility Score

    Assesses the highest level of mobility achieved in the ICU. The score range from 0 - 10, with higher score indicating better ouctome or greater mobility.

    Time frame: Day 1, Day 2 and Day 3 of post-CABG (+/- 1 day, or until day of ICU discharge)

  6. Pain Score

    Measure pain score of participant. The score range from 0 - 10, with higher score indicating worse outcome or greater pain intensity.

    Time frame: Day 1 of post-CABG, Day 2 of post-CABG, Day 3 of post-CABG, Day 4 of post-CABG, Day 5 of post-CABG (+/- 1 day, or until day of ICU discharge)

  7. Time on Mechanical Ventilation and Ventilator Free Days

    Time on Mechanical Ventilation of participant in hours and Ventilator Free Days in days during ICU stay

    Time frame: 3-months post-CABG (+/- 1 month)

  8. 30-day readmission and mortality

    Incidence of readmission or death within 30 days after CABG

    Time frame: 3-months post-CABG (+/- 1 month)

  9. Short Form (36) Health Survey (SF-36)

    A survey that determines quality of life. The summary of the health components Physical Health Component (PCS) and Mental Health Component (MCS) are derived from eight subscales PF, RP, BP, GH, VT, SF, RE, MH), where the minimum score represents the worst health and the maximum score represents the best health. The minimum and maximum score of the subscales are as follow: 1. PF (minimum 19.3, maximum 57.5), 2. RP (minimum 21.2, maximum 57.2), 3. BP (minimum 21.7, maximum 62.0), 4. GH (minimum 19.0, maximum 66.5), 5. VT (minimum 22.9, maximum 70.4), 6. SF (minimum 17.2, maximum 57.3), 7. RE (minimum 14.4, maximum 56.2), 8. MH (minimum 11.6, maximum 63.9).

    Time frame: 2 weeks prior to operation (Baseline measurement, +/- 2 weeks), 3-months post-CABG (+/- 1 month)

07

Study locations

1 of 1 sites recruiting
  • National University Hospital
    Singapore, 119074, Singapore
    Recruiting
    • Su Ren Wong · Contactsu_ren_wong@nuhs.edu.sg · +65-90279451
    • Megan HL Tan · Contactmegan_huei_lin_tan@nuhs.edu.sg
    • Su Ren Wong · Principal investigator
    • Geetha Kayambu · Sub investigator
    • Graeme MacLaren · Sub investigator
    • Ramanathan Kollengode Ramaswamy · Sub investigator
    • Guohao Chang · Sub investigator
    • Lian Kah Ti · Sub investigator
    • Kit Cheng Ting · Sub investigator
    • Bee Choo Tai · Sub investigator
    • Hui Minn Chan · Sub investigator
    • Rachel Lee · Sub investigator
    • Hui Min Chua · Sub investigator
    • Ong Li Xin · Sub investigator
    • Najjar Raymond · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2026, 31 months after the start.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 31 months is above that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartActual
Jan 8, 2024
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06107517
Collaborators
National University of Singapore, National Medical Research Council (NMRC), Singapore
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Jan 8, 2024
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Mar 30, 2026

Study contacts

Megan HL Tan
Contact
megan_huei_lin_tan@nuhs.edu.sg
+65-96280613
Michell KS Low
Contact
michell_kai_sian_low@nuhs.edu.sg
+65 83164092
Su Ren Wong
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion